

PRECEPTORSHIP PROGRAMME

Ovarian Cancer

Multidisciplinary management,
standards of care and future
perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

6-7 SEPTEMBER 2021

Co-Chairs

Sandro Pignata, Italy

Isabelle Ray-Coquard, France

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

OVARIAN CANCER

Multidisciplinary management, standards of care
and future perspectives

6-7 September 2021

CO-CHAIRS: Sandro Pignata, Italy
Isabelle Ray-Coquard, France

SPEAKERS: Gustavo Baldassarre, Italy
Michele Bartoletti, Italy
Claire Falandry, France
Christina Fotopoulou, United Kingdom
Philipp Harter, Germany
Rebecca Kristeleit, United Kingdom
Domenica Lorusso, Italy
Christian Marth, Austria
Glenn McCluggage, United Kingdom
Iain McNeish, United Kingdom
Xavier Paoletti, France

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
- To understand the importance of biology and pathology of common and rare ovarian tumours
- To understand the options for treatment of recurrent disease and how treatment-decisions are made
- To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- To learn about the management of patients with symptoms of the disease and the side-effects of treatment

ACCREDITATION

The programme of this virtual event has been accredited with **7 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Monday, 6 September 2021

14:30-14:40 10'	Welcome and introduction	Sandro Pignata, IT Isabelle Ray-Coquard, FR
14:40-15:40 60'	SESSION 1 Early stage	Chair/Moderator: Sandro Pignata, IT
15'	Pathology and biology of early epithelial ovarian cancer and rare ovarian tumours	Glenn McCluggage, UK
15'	Surgery for early ovarian cancer: Staging and conservative surgery	Christian Marth, AT
15'	Clinical management of early ovarian cancer	Isabelle Ray-Coquard, FR
15'	Q&A	All
15:40-16:00	Break	
16:00-17:25 85'	SESSION 2 Advanced disease	Chair/Moderator: Isabelle Ray-Coquard, FR
15'	Biology and staging of high grade tubo-epithelial cancers including HRD	Iain McNeish, UK
15'	Surgery for advanced ovarian cancer	Christina Fotopoulou, UK
15'	First-line chemotherapy treatment: Current results and challenges	Sandro Pignata, IT
3x10'	3 x Participant clinical case discussion	All
10'	Q&A	All
17:25-18:25 60'	SESSION 3 Rare cancers and complex situation	Chair/Moderator: Sandro Pignata, IT
15'	Genomic profiling for rare ovarian cancer	Michele Bartoletti, IT
15'	Rare non-epithelial tumours: Treatment	Domenica Lorusso, IT
15'	Rare epithelial tumours: Treatment & Networks for research	Isabelle Ray-Coquard, FR
15'	Q&A	All

Tuesday, 7 September 2021

14:30-15:50 80'	SESSION 4 Recurrent disease	Chair/Moderator: Isabelle Ray-Coquard, FR
20'	Overview of treatment of recurrent ovarian cancer including place of anti angiogenics and parpi	Rebecca Kristeleit, UK
20'	Place of surgery in relapse	Philipp Harter, DE
3x10'	3 x Participant clinical case discussion	All
10'	Q&A	All
15:50-16:05	Break	

16:05-17:05 60'	SESSION 5 To prepare the future	Chair/Moderator: Sandro Pignata, IT
15'	Biology of drug resistance	Gustavo Baldassarre, IT
15'	A clinician's guide to cancer genomics	Iain McNeish, UK
15'	Clinical trial design, meta-analysis, PRO and QoL	Xavier Paoletti, FR
15'	Q&A	All
17:05-18:05 60'	SESSION 6 The future	Chair/Moderator: Isabelle Ray-Coquard, FR
15'	Management of ovarian cancer in the elderly	Claire Falandry, FR
15'	Immunotherapy: Current evidence and future prospects	Domenica Lorusso, IT
15'	Novel treatment pathways beyond immunotherapy: Horizon scanning	Rebecca Kristeleit, UK
15'	Q&A	All
18:05-18:15 10'	Conclusion and farewell	Sandro Pignata, IT Isabelle Ray-Coquard, FR

Note: Each 10 min slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion